Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00968942 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety Study of RT001 to Treat Moderate to Severe Lateral Canthal Lines
A Phase 2 study of Facial Wrinkles and Lateral Canthal Lines, sponsored by Revance Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 36
- Enrollment target
- 1
- Study location
NCT00968942 is a Phase 2 study of Facial Wrinkles and Lateral Canthal Lines that has completed, run by Revance Therapeutics. The registered enrollment target is 36 participants, below the 81-participant average among 6 other Facial Wrinkles trials with a reported enrollment target (56% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00968942, a Phase 2 study of Facial Wrinkles and Lateral Canthal Lines, has completed, sponsored by Revance Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 36 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to evaluate the safety and efficacy of 2 sequential doses of RT001 compared to placebo gel to treat moderate to severe lateral canthal lines in adults.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Botulinum Toxin Type A
Study Locations (1)
Florida
- Dermatology Research Institute, LLC. - Coral Gables
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2009-08 |
| Est. Completion | 2009-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00968942
The ClinicalTrials.gov registry entry for NCT00968942 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 81-participant average among 6 other Facial Wrinkles trials with a reported enrollment target (56% lower). The listed sponsor is Revance Therapeutics, which has 27 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Facial Wrinkles appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00968942 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.
Frequently Asked Questions
What is clinical trial NCT00968942 about?
NCT00968942 is a clinical study titled "Efficacy and Safety Study of RT001 to Treat Moderate to Severe Lateral Canthal Lines". The purpose of this study is to evaluate the safety and efficacy of 2 sequential doses of RT001 compared to placebo gel to treat moderate to severe lateral canthal lines in adults.
What is the current status of trial NCT00968942?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 36 participants. The study started on 2009-08. Estimated completion is 2009-10.
What conditions does trial NCT00968942 study?
This clinical trial studies the following conditions: Facial Wrinkles, Lateral Canthal Lines, Crows Feet.
What interventions are being tested in trial NCT00968942?
The interventions under investigation include: Placebo (DRUG), Botulinum Toxin Type A (DRUG).
Who is sponsoring clinical trial NCT00968942?
This trial is sponsored by Revance Therapeutics, which has 27 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00968942 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Facial Wrinkles
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Cryo-Touch II for the Treatment of Wrinkles
COMPLETED · Phase 2
-
Safety and Efficacy Study of RT001 to Treat Moderate to Severe Lateral Canthal Lines
COMPLETED · Phase 2
-
A 4-Arm Efficacy and Safety Study of RT001 for the Treatment of Moderate to Severe Lateral Canthal Lines in Adults
COMPLETED · Phase 2
-
Split-Face Prospective Study Comparing Botox to Xeomin for the Treatment of Facial Wrinkles
COMPLETED · NA
-
A Study to Compare Subject Comfort During and After Injections With the Study Products and the Safety of the Non-FDA Approved Product for the Correction of Nasolabial Folds (NLFs)
COMPLETED · Phase 3
-
PicoWay™ 730 Resolve Fusion for Benign Pigmented Lesions and Wrinkles
COMPLETED · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.